IM Bands in Inactive Hepatic CE

December 30, 2025 updated by: Raffaella Lissandrin, Fondazione IRCCS Policlinico San Matteo di Pavia

Comparison of Immunoblotting Bands Pattern in Patients With Treated Versus Untreated Inactive Echinococcal Cysts of the Liver

Comparison of immunoblotting bands pattern in patients with treated versus untreated echinococcal cysts of the liver

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
    • PV
      • Pavia, PV, Italy, 27100
        • Recruiting
        • Fondazione IRCCS Policlinico San Matteo di Pavia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients affected by cystic echinococcosis of the liver.

Description

Inclusion Criteria:

  • Only Hepatic echinococcal cysts
  • Age > 18 years
  • At leat 2 clinical evaluation

Exclusion Criteria:

  • different location of echinococcal cysts
  • Age < 18 years --less then 2 clinical evalutation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients with spontaneously inactivated hepatic CE cysts with positive WB and RT t differente times from diagnosis.
Time Frame: from September 2024 to September 2026
from 0 to 100%
from September 2024 to September 2026

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of cysts that remaine inactive after treatment or reactivate
Time Frame: from september 2024 to September 2026
from 0 to 100%
from september 2024 to September 2026
Percentage of patients with inactivated cysts after treatment with positive WB results at different time point from the first observation of an inactive stage.
Time Frame: from September 2024 to September 2026
from 0 to 100%
from September 2024 to September 2026

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 23, 2025

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

December 30, 2025

First Submitted That Met QC Criteria

December 30, 2025

First Posted (Estimated)

January 12, 2026

Study Record Updates

Last Update Posted (Estimated)

January 12, 2026

Last Update Submitted That Met QC Criteria

December 30, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 08075323

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cystic Echinococcosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe